Sustainability of Pneumococcal Conjugate Vaccination in Ghana: a Cost-effectiveness Analysis in the Context of Donor Transition

Overview

Journal Front Public Health

Specialty Public Health

Date 2024 Aug 16

PMID 39148654

Authors

Abdul-Mumin Ibrahim

Richmond Owusu

Justice Nonvignon

Affiliations

Soon will be listed here.

Abstract

Background: Streptococcus pneumonia is responsible for 18% of infant deaths in Ghana. With co-financing from Gavi in 2012, Ghana introduced the PCV13 into the childhood immunization programme to reduce the burden of Streptococcus pneumonia. However, Ghana will graduate to the Gavi fully self-financing phase in 2026, when the nation assumes full responsibility of paying for the PCV13. This research aims to evaluate the health impact and cost-effectiveness of PCV13 immunization in Ghana since its implementation and after the cessation of support from Gavi.

Methods: We used the UNIVAC tool to evaluate two main scenarios of cost-effectiveness, from vaccine introduction (2012-2025) and after Gavi transition (2026-2031) in comparison with no vaccination. The sources of data include national data, international estimates and expert opinion. Cost was considered from both the government and societal perspectives. We discounted health outcomes at 3%. Currency values were stated in US Dollars. We tested the robustness of the base case results by performing scenario and sensitivity analyses.

Results: PCV13 will reduce the pneumococcal disease burden by 48% from 2012 to 2031. The vaccination programme costs are USD 130 million and USD 275 million in 2012-2025 and 2026-2031 respectively. It also has a budget impact of USD 280 million for the 2026-2031 period from the perspective of government. The incremental cost-effectiveness ratios are USD 89 and USD 73 respectively from the perspectives of government and society in 2012-2025. The incremental cost-effectiveness ratios are USD 530 and USD 510 respectively from the perspectives of government and society in 2026-2031.

Conclusion: The PCV13 vaccination programme in Ghana is cost-effective at 50% GDP per capita threshold even when Gavi withdraws co-financing support from 2026 onwards.

Citing Articles

Cost-effectiveness and budget impact of covering Burkitt lymphoma in children under Ghana's National Health Insurance Scheme.

Owusu R, Pritchard D, Heupink L, Gulbi G, Asare B, Amankwah I Cost Eff Resour Alloc. 2025; 23(1):1.

PMID: 39871292 PMC: 11773855. DOI: 10.1186/s12962-025-00603-1.

References

Chen C, Cervero Liceras F, Flasche S, Sidharta S, Yoong J, Sundaram N . Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2018; 7(1):e58-e67. PMC: 6293964. DOI: 10.1016/S2214-109X(18)30422-4. View

Ayieko P, Griffiths U, Ndiritu M, Moisi J, Mugoya I, Kamau T . Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One. 2013; 8(6):e67324. PMC: 3691111. DOI: 10.1371/journal.pone.0067324. View

Salomon J, Haagsma J, Davis A, Maertens de Noordhout C, Polinder S, Havelaar A . Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015; 3(11):e712-23. DOI: 10.1016/S2214-109X(15)00069-8. View

Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A . Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012; 7(4):e36226. PMC: 3340347. DOI: 10.1371/journal.pone.0036226. View

Lucero M, Dulalia V, Nillos L, Williams G, Parreno R, Nohynek H . Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009; (4):CD004977. PMC: 6464899. DOI: 10.1002/14651858.CD004977.pub2. View

Clark A, Jauregui B, Griffiths U, Janusz C, Bolanos-Sierra B, Hajjeh R . TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine. 2013; 31 Suppl 3:C19-29. DOI: 10.1016/j.vaccine.2013.05.045. View

Dadzie D, Addo-Lartey A, Peprah N, Kenu E . Evaluation of surveillance system for pneumonia in children below five years, Tema Metropolis, Ghana, 2012 - 2016. Ghana Med J. 2021; 54(2 Suppl):11-17. PMC: 7837343. DOI: 10.4314/gmj.v54i2s.3. View

Owusu R, Mvundura M, Nonvignon J, Armah G, Bawa J, Antwi-Agyei K . Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness. PLOS Glob Public Health. 2023; 3(8):e0001328. PMC: 10411789. DOI: 10.1371/journal.pgph.0001328. View

Wahl B, OBrien K, Greenbaum A, Majumder A, Liu L, Chu Y . Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018; 6(7):e744-e757. PMC: 6005122. DOI: 10.1016/S2214-109X(18)30247-X. View

10.

Woods B, Revill P, Sculpher M, Claxton K . Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016; 19(8):929-935. PMC: 5193154. DOI: 10.1016/j.jval.2016.02.017. View

11.

Knoll M, Bennett J, Garcia Quesada M, Kagucia E, Peterson M, Feikin D . Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms. 2021; 9(4). PMC: 8066045. DOI: 10.3390/microorganisms9040742. View

12.

Leech A, Kim D, Cohen J, Neumann P . Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018; 21(7):759-761. PMC: 6041503. DOI: 10.1016/j.jval.2017.12.016. View

13.

Appiah-Korang L, Asare-Gyasi S, Yawson A, Searyoh K . Aetiological agents of ear discharge: a two year review in a teaching hospital in Ghana. Ghana Med J. 2015; 48(2):91-5. PMC: 4310331. DOI: 10.4314/gmj.v48i2.6. View

14.

Jauregui B, Janusz C, Clark A, Sinha A, Garcia A, Resch S . ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015; 33 Suppl 1:A21-7. DOI: 10.1016/j.vaccine.2014.12.080. View

15.

Vodicka E, Nonvignon J, Antwi-Agyei K, Bawa J, Clark A, Pecenka C . The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. Vaccine. 2021; 40 Suppl 1:A85-A93. DOI: 10.1016/j.vaccine.2021.07.027. View

16.

Whitney C . Measuring progress on preventing pneumonia deaths: are we there yet?. Lancet Infect Dis. 2017; 17(11):1100-1101. DOI: 10.1016/S1473-3099(17)30481-4. View

17.

Ezoji K, Yaghoubi M, Nojomi M, Mahmoody S, Zahraie S, Moradi-Lakeh M . Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran. East Mediterr Health J. 2019; 25(10):686-697. DOI: 10.26719/emhj.19.039. View

18.

Pecenka C, Usuf E, Hossain I, Sambou S, Vodicka E, Atherly D . Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications. BMJ Glob Health. 2021; 6(12). PMC: 8679103. DOI: 10.1136/bmjgh-2021-007211. View

19.

Mao W, McDade K, Huffstetler H, Dodoo J, Abankwah D, Coleman N . Transitioning from donor aid for health: perspectives of national stakeholders in Ghana. BMJ Glob Health. 2021; 6(1). PMC: 7812084. DOI: 10.1136/bmjgh-2020-003896. View

20.

Abbey M, Afagbedzi S, Afriyie-Mensah J, Antwi-Agyei D, Atengble K, Badoe E . Pneumonia in Ghana-a need to raise the profile. Int Health. 2018; 10(1):4-7. DOI: 10.1093/inthealth/ihx062. View